|Table of Contents|

Advances in research on correlation between ovarian neoplasms and blood lipid levels and application of statins in ovarian cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 04
Page:
659-662
Research Field:
Publishing date:

Info

Title:
Advances in research on correlation between ovarian neoplasms and blood lipid levels and application of statins in ovarian cancer
Author(s):
Xu Huimin; Lou Ge
Department of Gynaecology,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China.
Keywords:
ovarian neoplasms; lipid level; statins
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2020.04.032
Abstract:
Ovarian cancer is the most common cause of death in gynecologic malignancies.The causes and influencing factors of its occurrence and development are complex and changeable,which has had a huge negative impact on the health and quality of life of modern women in recent years.Early (I/II) ovarian cancer has a good prognosis,with 5-year survival rate of more than 90%,but about 80% of all recurrent cases are in late (III/IV),with 5-year survival rate of only 11%.At present,some studies have shown that the level of blood lipid is related to ovarian tumors.This article mainly discusses whether dyslipidemia is different in ovarian benign tumors and ovarian cancer and whether other statins are used in ovarian cancer.

References:

［1］Zhang Y,Liu Y,Li L,et al.High resolution mass spectrometry coupled with multivariate data analysis revealing plasma lipidomic alteration in ovarian cancer in Asian women［J］.Talanta,2016(150)：88-96.
［2］Sun Y,Meng H,Jin Y,et al.Serum lipid profile in gynecologic tumors:A retrospective clinical study of 1,550 patients［J］.Eur J Gynaecol Oncol,2016,37(3):348-352.
［3］Stine JE,Guo H,Sheng X,et al. The HMG-CoA reductase inhibitor simvastatin,exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer［J］.Oncotarget,2016,7(1):946-960.
［4］SUN D.Clinical study on blood lipid levels in patients with different types of tumor［J］.Guide of China Medicine,2018,16(08)：31.［孙德.不同类型肿瘤患者血脂水平的临床研究［J］.中国医药指南,2018,16(08)：31.］
［5］WANG H,WU XH,SHI L.Lysophosphatidic acid promotes transplanted tumor growth of human epithelium ovarian cancer in nude mice［J］.J South Med Univ,2013,27(2):228-231.［王辉,吴小华,史丽.溶血磷脂酸诱导人卵巢上皮癌裸鼠腹腔移植瘤生长研究［J］.南方医科大学学报,2013,27(2):228-231.］
［6］Robert L Coleman,Alan Gordon,James Barter,et al.Early changes in CA125 after treatment with pegy lated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients［J］.The Oncologist,2014(12):72-78.
［7］Chen W,Zheng R,Baade,et al.Cancer statistics in China,2015［J］.CA:A Cancer Journal for Clinicians,2016,66(2):115-132.
［8］Qadir MI,Malik SA.Plasma lipid profile in gynecologic cancer［J］.Eur J Gynaecol Oncol,2008,29(2):158-161.
［9］ZHOU X,ZHOU YJ,LI XC.Diagnostic values of LDL and ox-LDL in patients with epithlial ovarian cancer and their relationship with prognosis［J］.Laboratory Medicine and Clinic,2015,12(23):3494-3496.［周晅,周彦杰,李新春.上皮性卵巢癌患者LDL与ox-LDL的诊价值及与预后［J］.检验医学与临床,2015,12(23):3494-3496.］
［10］Li AJ,Elmore RG,Chen IY,et al.Serum low-density lipoprotein levels correlate with suivival in advanced stage epithelial ovarian cancers［J］.Gynecol Oncol,2010,116(1):78-81.
［11］LU BM,XING W.Correlation between serum low-density lipoprotein levels and prognosis of patients with epithelial ovarian cancer［J］.Modern Medicine Journal of China,2014,16(05):55-57.［陆宝明,幸薇.血清低密度脂蛋白水平与上皮性卵巢癌患者预后的相关性［J］.中国现代医药杂志,2014,16(05):55-57.］
［12］Buss LA,Dachs GU.The role of exercise and hyperlipidaemia in breast cancer progression［J］.Exerc Immunol Rev,2018(24):10-25.
［13］Kitson SJ,Lindsay J,Sivalingam VN,et al.The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer:A prospective case control study［J］.Gynecol Oncol,2018,148(1):154-160.
［14］Bjorge T,Lukanova A,Tretli S,et al.Metabolic risk factors and ovarian cancer in the metabolic syndrome and cancer project［J］.Int J Epidemiol,2011,40(6):1667-1677.
［15］LUO W,GUO Y,DING F.Study on the blood lipid and the blood glucose of patients with coronary artery atherosclerosis［J］.Chinese Journal of Laboratory Diagnosis,2018,22(06):964-967.［罗薇,郭英,丁霏.冠状动脉粥样硬化患者血脂及血糖水平的研究［J］.中国实验诊断学,2018,22(06):964-967.］
［16］Constantine EK,Eddy D,Digna R,et al.CETP inhibition:Past failures and future hopes［J］.Clinical Medicine Insights Cardiology,2016(10):37-42.
［17］Jafi H,Alsheikh-Ali AA,Karas RH.Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy［J］. Am Coll Cardiol,2010,55(25):2846-2854.
［18］Silvente-Poirot S,Poirot M.Cholesterol metabolism and cancer:The good,the bad and the ugly［J］.Curr Opin Pharmacol,2012(6):673.
［19］Yang HH,Chen XF,Hu W,et al.Lipoprotein(a) level and its association with tumor stage in male patients with primary lung cancer［J］.Clin Chem Lab Med,2009,47(4):452-457.
［20］Lippi G,Franchini M,Salvagno GL,et al.Lipoprotein(a) and cancer:Antineoplastic effect besides its cardiovascular potency［J］.Cancer Treat Rev,2007,33(5):427-436.
［21］Borena W,Stocks T,Jonsson H,et al.Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study［J］.Cancer Causes Control,2011(22):291.
［22］Tan SF,Yang HJ,Li SQ,et al.Changes of blood lipid levels in cancer patients［J］.Chinese Journal of Microcirculation,2013(03):1705-1740.
［23］Kato S,Smalley S,Sadarangani A,et al.Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase［J］.Cell Mol Med,2010(14):1180-1193.
［24］Jiang P,Mukthavaram R,Chao Y,et al.In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells［J］.Br J Cancer,2014(111):1562-1571.
［25］Pinai-Fernandez,Casal-Dominguze M,Mammen AL,et al.Statin：Pros and Cons［J］.Med Clin (Barc),2018,150(10):398-402.
［26］Kobayashi Y,Kashima H,Wu RC,et al.Mevalonate patway antagonist suppresses formation of serous tubal intreapithelial carcnoma and ovarian carcinoma in mouse models［J］.Clin Cancer Res,2015,21(20):4652-4662.
［27］Jones HM,Fang Z,Sun W,et al.Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro［J］.Am J Cancer Res,2017,7(12):2478-2490.
［28］Stine JE,Guo H,Sheng X,et al.The HMG-CoA reductase inhibitor,simvastatin,exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer［J］.Oncotarget,2016(7):946-960.
［29］Lee SJ,Lee I,Lee J,et al.Statins,3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors,potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin 2,BiP,and Hsp90alpha in human colorectal cancer［J］.Br J Cancer,2014(111):497-505.
［30］Fang Z,Tang Y,Fang J,et al.Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR,ERK and JAK2/STAT3 pathway［J］. PLoS One,2013(8):e62823.
［31］Couttenier A,Lacroix O,Vaes E,et al.Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study［J］. PLoS One,2017,12(12):e0189233.
［32］Vogel TJ,Goodman MT,Li AJ,et al.Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer［J］.Gynecol Oncol,2017,146(2):340-345.
［33］Zhang Ting,Cui Ge,Feng Wenming,et al.Correlation analysis of glucose and lipid metabolism indexes and clinicopathological features in patients with gastric cancer［J］.National Medical Journal of China,2016,96(32):2545-2547.
［34］Touvier M,Fassier P,His M,et al.Cholesterol and breast cancer risk:A systematic review and Meta-analysis of prospective studies［J］.Br J Nutr,2015,114(3):347-357.
［35］Bull CJ,Bonilla C,Holly JM,et al.Blood lipids and prostate cancer:A mendelian randomization analysis［J］.Cancer Med,2016,5(6):1125-1136.

Memo

Memo:
-
Last Update: 2019-12-26